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Abstract: The epidemic of the century, Diabetes Mellitus (DM) is continuously rising.
Intensive research is urgently needed whereby experimental models represent an essential tool
to optimise the diagnostic strategy and to improve therapy. In this review, we describe the central
principles of the metabolic tests available in order to study glucose and insulin homeostasis in
mice, focusing on the most widely used – the glucose and insulin tolerance tests. We provide
detailed experimental procedures as well as the practical implementation of these methods and
discuss the main factors that should be taken into account when using this methodology.
Keywords: metabolic tolerance test, T2DM, obesity, metabolic syndrome, insulin resistance,
glucose intolerance
Introduction
Diabetes mellitus (DM) is a serious threat to the health that affects people from
basically every country in the world. Globally, the number of people with DM has
quadrupled in the past three decades. Nowadays, about 1 in 11 adults worldwide have
DM, 90% of whom have type 2 DM (T2DM). This escalation is partly due to increasing
rates of overweight, obesity, and a sedentary lifestyle.1,2 In order to mitigate this
pandemic, there is an urgent need for new approaches to handle T2DM, obesity and
their associated complications. This requires the use of animal models to develop,
validate and optimize novel therapeutics for their safe use in patients.3 However, in
order to improve the transition from bench to bedside, researchers must not only
carefully select the appropriate in vivo model but also draw the right conclusions.
The metabolic tolerance tests (MTT) have been the mainstay for diagnosing
diabetes for decades. These tests represent simple but powerful screening methods
to diagnose impaired carbohydrate metabolism, glucose intolerance and early
Insulin Resistance (IR).4
Generally, theMTTarewidely used in the literature, are relatively easy to perform and
require only basic experience and handling skills with lab animals. However, the outcome
of the tests and reproducibility of results can have great variability if the procedure is not
correctly performed. By using the most relevant literature5–8 and our experience,9–11 in
this review, we standardize and describe easy-to-follow detailed protocols for mainMTT,
and highlight the advantages, limitations and important caveats of each of these methods.
Basic Considerations
Before the beginning of any MTT, it is critical that researchers seriously take into
account the impact of several factors, including mouse strain, age, gender, control
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groups, husbandry and fasting conditions. All these details
should be also clearly and accurately described in the
methodological section of the publication. Most critical
factors that can lead to misinterpretation of phenotypic
results are specified below and outlined in Table 1 (bullet
points).
Animal Husbandry
Animals should be housed under standard pathogen-free
conditions and regular 12:12-hr light–dark cycle. The
light–dark regime should be strictly followed and
researchers should eschew to perform experiments or
even enter the mouse room during the dark cycle to
avoid any potential impact on the animal´s metabolism.
Along these lines, the time of the day during which the
metabolic tests are to be conducted represents also a key
factor. Over a 24-hr period, mice, similarly to humans,
experience variations in glucose and metabolic hormones
which can affect the interpretation of results. The circa-
dian rhythm of glucose concentration – is characterized
by a peak in the middle of the photophase (light period)
decreasing to the beginning of the scotophase (dark
period).12 It is therefore important for all experiments
in a given study to be carried out at the same time of
the day.5
From current codes of practice, assuming the daily cost
of animal housing, there is a strong motivation to group
housing of mice. Whilst the natural behaviour of female
mice simplifies their housing in groups even during
extended periods of chronic treatment, male mice do not
naturally share territories, and aggression can be a serious
welfare problem. Even without aggression, the distribution
of food, water, resting places between animals within
a group can be affected by the subordination and social
hierarchies. Therefore, if harmonious grouping is not pos-
sible, providing male mice with a more suitable environ-
ment through single-housing may be more favourable
from the perspectives of research validity. However, for
a better comparison between the groups, it is recommend-
able to have the same number of mice per cages during the
whole experimental period.13
It is also extremely important to reduce environmental
stress of the experimental animals, since it is well estab-
lished that stress response and subsequent elevations in
adrenaline and noradrenaline have major physiological
effects on glucose homeostasis. This includes plasma glu-
cose concentrations in mice which are significantly ele-
vated following primary handling or cage transporting.14
Hence, a quiet environment nearby the mice cages is
essential and any disturbance such as noise, lightening
vibration, strong odours should be minimized. The harm-
ful influence of stress during experimental protocols can
be potentially reduced with acclimatization of mice to
being handled. It is advisable to handle experimental
mice at least once every week after weaning, for example,
by weighting. It is also recommendable to transport mice
to the experimental room in their home cages, at least 1 hr
prior to the start of metabolic testing.5,7,15,16 It is also
critical to state, that many models of diet-induced obesity
or diabetes are associated with polyuria and require more
frequent changes of the bedding in the cage.17
Fasting
Accurate metabolic tolerance tests depend on the appro-
priate preparation of the mice. The proper fasting is essen-
tial to provide stable baseline measurements and to obtain
consistent excursions in plasma glucose after tolerance
tests. Fasting for 10–12 hrs (overnight) is a standard pro-
cedure and commonly used in most metabolic studies.12
Mice consume most of their daily calories during the dark
cycle. Therefore, overnight fasting provokes a catabolic
Table 1 Bullet Points: General Experimental Pre-Settings, Quick
Procedure and Considerations for MTT
Experimental Pre-Settings
● Quiet and stress-free environment
● Standardized and persistent conditions through the whole experi-
mental period (i.e. time of fasting, route of administration, dosage
of glucose/Insulin, brand of glucometer)
Quick Assay Procedure
● Pre – fasting for 6 or 12 hrs
● Measure mice body weight after fasting
● Calculate the amount of glucose and insulin needed
○ GTT. Volume for injection = 7.5 x Body weight. From 20%
Glucose stock solution.
○ ITT. Volume for injection = 3 x Body weight. From 0.25 UI/mL
Insulin in saline solution (Ex. 9.975 mL saline solution + 25 µL
Insulin 100 UI/mL).
● Cut tail and measure basal glucose in the blood
● i.p. with a time-lapse between mice of 3 min.
● Repeat determination of blood glucose concentration after 15, 30,
60, 90 and 120 min.
Considerations for Minimize Intra-Group Differences
● Genetically identically inbred
● Similar age
● Same gender
● Minimum 5 animals per group
● Perfectly matched control group, preferentially littermates
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state in mice, dramatically mobilize the glucose reservoirs,
depletes liver glycogen stores and produces low (Figure 1),
stable baseline blood glucose levels with small
variability.5,7
However, several recent studies have expressed con-
cern since overnight fasting is not ideal and may induce
a state more similar to starvation in humans. Rodents are
nocturnal feeders, and their metabolic rate is much higher
than humans, meaning that an overnight fast is a relatively
long time for mice to be deprived of food. In lean mice,
overnight fasting reduces lean body mass by ~15%.6 It is
also worth to remark that muscle shows increased insulin
sensitivity following an overnight fast but not after shorter
fasting periods of 5–6 hrs. Thus, sometimes the differences
in glucose intolerance between chow- and high-fat diet
(HFD)-fed animals are less evident following standard
overnight (12 hr) fast compared with shorter fasting
times.5,6
The protocols presented below can be used both for
overnight, and for morning fasting. However, the appro-
priate duration of fasting should be carefully chosen based
on the animal model and the planned scientific outcome. It
seems appropriate, in regard to both animal welfare, and
the validity of a study, to apply the shortest possible
fasting, and preferably to fast mice in the photophase, to
comply with the behaviour of the species.12 Nevertheless,
once the scheme of fasting is chosen, it should be kept
constant throughout the study. It is also necessary to
clearly report when animals were fasted and for how
long, in order to enhance the reproducibility of the study.
The Route of Administration
The most common methods for the administration of glu-
cose in mice during tolerance tests are oral gavage (OG) or
intraperitoneal injection (i.p.) injection. Both routes of
administration are generally accepted as appropriate; how-
ever, there are differences in the dynamics of the plasma
glucose and insulin response to oral and i.p. delivery that
should be considered. The plasma glucose levels are sig-
nificantly lower in response to oral GTT compared with
the same glucose dose administered i.p.5,6 It is mainly due
to the fact that glucose absorption from the gut leads to the
release of gastrointestinal hormones which significantly
potentiate glucose-induced insulin release with conse-
quently lower blood glucose levels compared with i.p.
injection.18 This would indicate that administration by
OG is the most physiological route of glucose entry.
However, based on our experience, oral administration is
very stressful for animals and more challenging from the
technical point of view, requiring a certain level of exper-
tise from the lab personnel performing the tests. It fre-
quently introduces significant variability in the outcome
and is often associated with incomplete glucose retention,
inadvertent tracheal administration, aspiration pneumonia,
oesophageal perforation and even gastric rupture, resulting
in the removal of animals from the study.19
One mechanism to minimise stress and complications
during oral gavage is to use anaesthesia when performing
MTT. Although anaesthesia may influence gastrointestinal
motility, blood glucose, plasma insulin dynamics and
therefore likely to give highly aberrant results.
Administration of isoflurane (2–3%) triggers a significant
increase in blood glucose concentration in both fasted and
fed rats and mice and induces an impaired glucose
tolerance.20 The i.p. injection with a combination of keta-
mine/xylazine (100 mg/kg/10 mg/kg) lowers insulin
responses and leads to severe hyperglycemia throughout
the experiment.21,22 Pentobarbital (40 mg/kg; i.p.) results
in both increased insulin secretion and impaired glucose
tolerance.22 Thus, the application of anaesthetics for meta-
bolic studies can potentially lead to a confounding inter-
pretation of the experimental data and should not be used
for MTTs in animals.
The i.p. route is an alternative method for glucose deliv-
ery successfully used in our laboratory for many years.9,10
Although i.p. delivery is considered a parenteral route of
administration, the pharmacokinetics of substances adminis-
tered i.p. are more similar to those seen after OG, because
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Figure 1 Graphical representation of the basal level of glucose after 6 and 12 hrs of
fasting. Due to the much intensive mobilization of the glucose reservoirs the basal
glucose values after overnight fasting are significantly lower compared to morning
fast. C57BL/6J, male mice, n= 5, **P<0.01.
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the primary absorption occurs into mesenteric vessels, and
drains into the portal vein, passing through the liver.23 It is
technically a simple procedure to perform; however, train-
ing and competent lab personnel should ensure that sub-
stances are delivered accurately and that needle perforation
of the gut or stomach lumen is avoided.23,24 In the protocols
presented below the i.p. route of administration has been
described as a basic method.
Strains of Mice
As it has been documented in many studies, mouse strains
exhibit remarkable differences in glucose homeostasis as
well as in their inherent predispositions to develop meta-
bolic disease.
Overall, the C57BL/6 mouse strain is generally sug-
gested to be the best strain for studying the metabolic
disease. For example, BALB/c mice display preserved
glucose tolerance and insulin action under HFD, and this
seems to be directly related to the lack of fat accumulation,
despite lipid accumulation in the muscle.25,26 There are,
nonetheless, important differences in the metabolic pheno-
types of the 6J and 6N substrains of the C57BL/6 mice. In
lean animals, 6J has higher glucose levels than 6N after
GTT.20,27 A similar situation was observed in HFD stu-
dies, where both substrains develop glucose intolerance,
but glucose levels were higher and insulin secretion was
significantly lower in the 6J.28,29 Therefore, the 6J sub-
strain of the C57BL/6 mouse has been widely used in
metabolic research, since these mice are more prone to
develop diabetes and diet-induced obesity. It is also the
background strain for ob/ob mouse. However, this sub-
strain cannot be used for the generation of knockout ani-
mals, since the 6J embryonic stem cells have low rates of
germline transmission. Recently, a stem cell (SC) line was
developed from the 6N substrain and selected for the
generation of targeted alleles in the International
Knockout Mouse Consortium (IKMC). Hence, for 6N-
derived knockouts the backcrossing strategy and consecu-
tive mating with 6J for few generations will eliminate
genetic variability as a complicating factor in comparing
results and, therefore, is strongly recommendable.28,30
Sex
Metabolic processes are known to be regulated in a sex-
specific manner. There are significant alterations in models
of glucose intolerance, IR and diabetes between male and
female mice. In general, male mice exhibit a stronger
phenotype than females. In turn, female animals manifest
improved glucose tolerance, likely due to greater insulin
sensitivity in liver, muscles and adipose tissue.31
These sex-related differences could be partly due to the
action of sex hormones. For example, the increased sensi-
tivity to insulin and lipogenesis observed in adipocytes from
females may account for their lower risk of IR and diabetes
incidence, despite similar or higher fat content than in males.
The decrease in estrogen and increase in testosterone levels –
which occur during menopause – are associated with loss of
subcutaneous as well as gain of visceral fat plus an increase
in IR.32,33 Moreover, the leptin signalling within the brain is
sexually different to influence the regulation of glucose
homeostasis and fat distribution, with females relying on
leptin to a greater extent than males.34
Thus, mouse sex can have a critical impact on the
performance of the metabolic model and only animals of
the same sex should be used in the studied cohorts.
Age
Aging is associated with a progressive deterioration in
most endocrine functions, responsible for metabolic dis-
orders. Many studies have reported hyperglycaemia,
declining glucose tolerance and increasing IR as an impor-
tant characteristic of aging. The main possible mechanisms
are alterations of hepatic glucose production, insensitivity
to the actions of insulin at the post-receptor/receptor
levels, and decreased insulin sensitivity of pancreatic
cells to insulinotropic gut hormones.35–37
However, in mice up to 20 months of age, the increase
in β-cell mass and in insulin secretion is capable of com-
pensating the growing IR. In contrast, at older ages (over
30 months), the β cell areas are decreased and, due to
a failure of β cell compensation, the insulin levels decline
and glucose intolerance is normally observed.38 The age-
related changes may be worsened due to obesity, renal
failure or the ingestion of certain drugs.35 Therefore, age
of animals plays an important role in the experimental
setting and metabolic tests should be carried out using age-
matched mice.5
Ethical Considerations
All MTTs should be carried only after authorisation from
the competent local Animal Ethics Committee by person-
nel trained in animal experimentation in strict compliance
with 3R (Replacement, Reduction and Refinement) princi-
ple for animal welfare postulated by Russel and Burch in
1959.39
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Hence, there are no physiologically significant
“Replacement” alternatives for MTT methods that allow
to avoid the use of animals, the “Reduction” and
“Refinement” tenets should be respected.
Specifically, “Reduction” refers to any strategy that
will result in fewer animals being used to obtain sufficient
data to answer the research question. From our own pre-
vious work, during MTT we observe approximately 25%
variation in the levels of basal glucose (after 12 hrs of
fasting) in the control animals as well as in the animals
treated with Western diet. Using the software G Power
V.3.1.9, a statistical power of 90% and a specific α error
probability of 0.05, we calculated that the minimal
required number of animals should be n = 5 per group.40
We also recommend repeating the tests several times using
different animals and combining the data sets.
“Refinement” requires the modification of husbandry
or experimental procedures to minimize pain and distress,
and to enhance the welfare of an animal used in the
experiment.39 According to Article 15 of the EU
Directive 2010/63 the metabolic tolerance tests as
a procedure resulting in short-term distress with no sig-
nificant impairment of the well-being or general condition
of the animals, should be classified as “mild” (the details
can be found at https://eur-lex.europa.eu/legal-content/EN/
TXT/?uri=celex%3A32010L0063). We think that the pre-
sented protocol entirely supports the “Refinement” princi-
ple and represents the basis of new animal welfare rules
that are presently implemented in many countries within
the European Framework.
Practical Implementation
Note: Please note that all procedures described in this
protocol should only be performed after institutional and
governmental approval as well as by staff that are techni-
cally proficient.
Glucose Tolerance Test (GTT)
The rise and fall of the blood glucose concentration fol-
lowing oral or intravenous administration of glucose “the
tolerance curve” has long been widely used both clinically
in patients and experimentally in animals as an index of
efficiency of the mechanisms regulating the concentration
of glucose in the blood.41 The fact that carbohydrate
ingestion results in blood glucose fluctuations had actually
been known, since the beginning of the 20th century. In
1940 Jerome W. Conn investigated this issue and primarily
implemented the GTT in his clinical research, showing
that a low-carbohydrate diet can cause deterioration of
glucose tolerance.
Nowadays, GTT is recommended by the World Health
Organization (WHO)42 and should be retained as
a diagnostic test to identify people with impaired glucose
tolerance. In fact, the use of fasting glucose alone for
screening fails to diagnose approximately 30% of people
with diabetes. This discrepancy is even more obvious in
the elder population. Around 70% of women and 48% of
men aged 50–89 years had new diagnosed diabetes at the
time they underwent oral glucose tolerance.43
In mice, the GTT is the simplest, and usually the first, test
applied to an animal model, and it provides a physiological
overview of any changes in glucose tolerance without deter-
mining the causative mechanisms. Briefly, mice are routinely
fasted before the administration of glucose. Baseline blood
glucose concentrations are taken before the application of
glucose, and the following measurements are made at certain
intervals over a span of 2 hrs.7 However, the influence of the
factors described above (see bullet points) on the glucose-
tolerance curve is well documented and should not be
ignored. Moreover, in order to avoid misinterpretation of
results, the conditions of the test should be standardized
and kept consistently during the running study.
Materials and Equipment (Figure 2A1)
● 1-mL Syringes and 25–27-G needle or, preferen-
tially, insulin syringes with needles
● Sharp scissors or surgical blades
● Hand-held whole-blood glucose meter (glucometer)
and corresponding glucose test strips.
Note: Typical hand-held glucometers are small in size and
require minor volumes of blood (typically 5 μL or less)
and therefore very practical when performing multiple
experiments at once. Nowadays many companies, for
example, Bayer (Barmen, German), Becton Dickinson
(BD) (New Jersey, USA), Roche (Basel, Switzerland)
and LifeScan (California, USA) provide a wide range of
glucometers. In our lab, we have traditionally used the
Aviva (Roche. REF: 06988580037) and Accu-Check
Aviva reactive strips (Roche REF:06916686001).
CAUTION: Given the differences between glucometers,
investigators should not change the brand of the monitor
through the whole experimental period. It is also recom-
mendable to evaluate the technical accuracy of the device
by comparing the results of glucometer against clinical
laboratory methods that use plasma/serum-based samples.
Dovepress Benedé-Ubieto et al
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CAUTION: Test strips should not be stored in closed
vehicles for extended periods and must be protected from
extremes of temperature and humidity.27
● 20% glucose stock solution.
Note: The stock solution can be prepared by dissolving 2
g of D-glucose (Sigma-Aldrich), in 10 mL of sterile saline
solution. The solution should be additionally sterilized by
passing it through a 0.2-μm filter into a sterile 15-mL
Falcon tube. Another option is to use commercially avail-
able 20% Glucose Solution for w/v Infusion (e.g. G-20%,
BRAUN, REF: 18046406).
Caution: Prior to administration the solution should be
pre-warmed to room or body temperature since injection
of cold substances can cause discomfort and drop in body
temperature of mice.
● Timer
● Lab balance and a beaker for weighing mice
● Experimental record sheet
Note: the attached example of the record sheet (see
Supplementary Table 1).
Experimental Protocol
1. Place mice in a clean cage without food. Keep the
water bottle.
Caution: Rodents are coprophagic, therefore for true fast-
ing conditions make sure that the cage is clean and has
new bedding.
2. Fast animals for either 10–12 hrs (overnight fast) or
for 6 hrs (morning fast).
Note: For overnight fasting, it is recommendable to remove
food just before the dark cycle, i.e. approximately at 7:00 pm.
The morning fasting can start at 8:00 a, until 2:00 pm.
3. Disinfect and clean bench with 70% EtOH and pre-
pare the work area with clean bench paper, balance,
blades, glucometer, syringes and needles.
4. Weight mice to the nearest 0.5 g (Figure 2B).
5. Based on the body weight, calculate the volume of
20% glucose solution required for i.p. injection.
Dosage: 1.5g of glucose/kg body mass
Formula: Volume of glucose for injection (μL) = 7.5
x body weight (g)
Example: for a 25 g mouse the volume for injection
should be 187.5 μL.
Note: There is no consistent amount of glucose admi-
nistered for GTT, with either 1 or 2 g/kg glucose being
typically used in the literature. However, in the HFD-fed as
well as in many other diabetic models, the body weight is
typically increased due to the fat mass, without proportio-
nately changes in lean mass which is in fact the principal
site of glucose disposal (muscle, brain and liver). Therefore,
obese mice could be misdiagnosed as glucose intolerants
simply because they received a disproportionately high
amount of glucose for the same lean body mass.44
Consequently, impaired glucose tolerance in obese mice
may only occur in response to a higher glucose loading
(1.5-2g/kg).5–7,45
Figure 2 Illustrative representation of the GTTexperimental protocol. (A1) Material and equipment required for GTT (20% glucose stock solution, 1-mL syringes, 25–27-G
needles, microsurgery scissors, glucose test strips, glucometer, lab balance). (A2) Material and equipment required for ITT (Insulin, sterile saline, 1-mL syringes, 25–27-G
needles, microsurgery scissors, glucose test strips, glucometer, lab balance). (B) Animals are weighed before the beginning of the experimental procedure for the estimation
of proper amount of Glucose/Insulin. (C) Tail tip of the manually restrained mouse is cautiously snipped with sharp scissors. (D) Measurement of the basal glucose. The
blood is obtained from the lifted tail of the mouse and the small drop is placed directly on a test strip. (E) i.p. injection. (F) Evaluation of blood glucose 30, 60, 90 and 120
mins after injection.
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6. Dispense the required volume of glucose solution for
each mouse into separate syringes.
7. Measure the basal levels of glucose.
Prepare the glucometer device: insert the test strip in the
direction of the arrows.
The meter turns on and beeps. Manually carefully restrain
the mouse. Pinch tail of the mouse between thumb and
forefinger, and cautiously snip a tip of the tail with sharp
scissors or a scalpel blade (Figure 2C).
Note: Typically, blood is taking from the tail tip. This
simple and fast technique does not require any special
surgical skills and can be easily performed in conscious
animals.5 However, the total amount of removed tail tissue
should be as small as possible. In most cases, 2 mm should
be adequate.
Obtain the blood drop by direct flow or by gentle
squeezing/massaging the tail (Figure 2D). Make sure that
the blood drop symbol flashes on the glucometer, place the
device firmly against the tail tip, touch the blood drop to
the front edge of the yellow window of the test strip. The
glucometer beeps and flashes once enough blood is placed
on the test strip. The test results appear on the display.
Return the mouse to the cage. Remove and discard the
used test strip. Record the result (t=0) in the experimental
record sheet. Proceed with the following mouse until the
basal levels of each mouse are collected.
8. Start with glucose i.p. injection (Figure 2E).
Prepare the syringe with an appropriate amount of glucose
solution. Hold the conscious mouse in a supine position
(abdomen side up) by the nape of the neck and extend by
pressing the tail to the palm of the hand with its head
pointed lower than the body.
Note: It is not necessary to sterilize the skin with
antiseptics as their use is ineffective and may only cause
additional disturbance to the animal. However, a new nee-
dle and syringe should be used for each mouse.
The injection should be performed in the animal’s lower
right quadrant of the abdomen in order to avoid damage to
the urinary bladder, cecum and other abdominal organs.
Insert the syringe at an approximately 30-400 angle to
horizontal. Push the needle to the depth in which the entire
bevel is within the abdominal cavity. Slowly inject the
appropriate amount of glucose solution into the intraperito-
neal cavity, pull the needle straight out and discard properly
into a sharp container without recapping. Carefully place
the animal back into the cage. Note the time-point of injec-
tion. Continue i.p. injections on subsequent mice, maintain-
ing a 2–5-min interval between animals.
Caution: The syringe plunger may be withdrawn prior
to injection. If urine, blood, or digesta are seen in the
needle hub, the needle should be withdrawn, replaced,
and repositioned prior to injection.
Caution: Too acute an angle of puncture should be
avoided, as it results in subcutaneous rather than intraper-
itoneal administration.23
Caution: In obese animals (upon HFD, for example),
almost the entire needle length may need to be inserted.
9. After 15 min, measure blood glucose levels with the
glucometer of each mouse in the same order as they
were injected.8 Resume to measure blood glucose
and get the values for 30, 60, 90 and 120 mins
after glucose injection (Figure 2F).
Note: The time management is very important; follow the
time intervals in the record sheet as closely as possible.
Note: For all subsequent measurements, in order to
avoid additional stress, instead of removing and restraining
the animal just lift the tail of the mouse, while leaving it in
the cage. Squeeze the tail and start the bleeding again by
removing the clot from the first incision, or gentle massage
the tail if blood flow is inadequate. Discard the first drop
and place the next small drop of blood on a new test strip
and document the measurements in the record sheet.
10. At the end of the experiment, make sure that further
blood loss from the incision is minimal by briefly
applying pressure to the incision (paper towel).
Place animals in a clean cage with water and food
available ad libitum for recovery.
Caution: Monitor the mice carefully at least for 2 hrs for
any abnormal behaviour.5
11. Alternatively, animals can be euthanized for tissue
collection directly after the procedure by carbon
dioxide (CO2) or cervical dislocation according to
the animal protocol and ethical regulations of the
region or country.
Insulin Tolerance Test (ITT)
To complement the analysis of glucose tolerance in vivo, it is
recommendable to include some measurements of IR to the
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study. Here, the ITT is the first-choice method. It is simple
and technically very similar to the GTT as it involves mon-
itoring of blood glucose levels over time, but in response to
insulin administration rather than glucose loading. Many of
the technical considerations that apply to GTTs also apply to
ITTs, even though with some additional factors.
Materials and Equipment (Figure 2A2)
1. Insulin syringes
2. Sharp scissors or surgical blades
3. Glucometer
4. Glucose Test Strips
5. 0.25 IU Insulin stock solution (e.g. Actrapid 100 UI/
mL. Human Insulin. Novo nordisk. REF: 775502.9)
Note: The stock solution can be prepared by diluting 100
IU human insulin (Actrapid) in sterile saline 1:400
(9,975mL of saline and 25 μL of 100 IU Insulin). The
solution should be mixed by vortexing and sterilized by
passing it through a 0.2-μm filter into a sterile 15-mL
Falcon tube.
6. 10% solution of glucose in case some animals
become hypoglycaemic (1 g of D-glucose in
10 mL of sterile saline)
7. Timer
8. Lab balance
9. Experimental record sheet (use template from
Supplementary Table 1)
Experimental Protocol
Note: TheMTTs are very exhausting for the mice. Therefore,
minimum of 1 week between tolerance tests should be taken
to regain lost blood volume and to recover.8
Note: most of the steps are similar to the GTT and
described above
1. Fast animals in a clean cage from 8:00 am until
2:00 pm (morning fast). Keep the water bottle!
Note: In order to avoid the hypoglycaemic conditions
during the test we recommend to do 6-hr fasting intervals.
2. Clean and prepare the working area as well as all
required materials.
3. Weight mice to the nearest 0.5 g and based on the
body weight calculate the volume of insulin solution
required for IP injection.7
Dosage: 0.75 IU insulin/kg body mass
Formula: volume of insulin for injection (μL) = 3
x body weight (g)
Example: for 25 g mouse the volume for injection
should be 75 μL.
Note: Take into account the differences in the fat mass
in obese animals, including those >40g on a HFD or such,
and increase the dose up to 2 U/kg.
4. Dispense the required volume of Insulin for each
mouse into separate syringes.
5. Measure the glucose at the basal level.
6. Perform i.p. injections of insulin, trying to maintain
at least a 2-min interval between animals.
7. Start the measurement of blood glucose at 15, 30, 60,
90 min after the insulin injection.
Note: If blood glucose drops below 20 mg/dL, or animal
appears hypoglycaemic (tremor, heightened anxiety or
apathy, paresthesia, loss of consciousness and rarely con-
vulsions), inject i.p. 300 μL of the glucose solution pre-
pared above to rescue the mouse and prevent shock. Ignore
the data from this animal.
Note: Due to the short half-life of insulin (10 min), the
blood glucose measurements are usually limited to 90 min
after i.p. injection.7
8. At the end of the experiment provide food to each
mouse and observe them at least for a minimum of 2
extra hours.
9. Alternatively, mice can be euthanized for tissue
collection.
Interpretation of Results
The results should be presented as a time course of
absolute blood glucose measurements (mg/dL) and as
the area under the curve (AUC). The statistical compar-
ison of glucose levels can be processed through an
analysis of variance by any statistical and graphing
program, for example, Prism 8.0 (GraphPad Software,
San Diego, CA).
A typical GTT for chow-fed female 20 weeks old
mice with C57BL/6J background after overnight fast-
ing is shown in Figure 3A. The following parameters
can be analysed here: glucose concentration at basal
level and at each time point after glucose administra-
tion, the dynamic of the curve decrease. Generally,
a healthy mouse with normal glucose tolerance shows
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a characteristic rapid rise in blood glucose, reaching its
peak 15 min after the glucose challenge. Subsequent
glucose uptake, primarily conducted by muscle, fat and
liver-tissue leads to a gradual decrease of the blood
glucose concentration to the normal level after approxi-
mately 60–90 min.
Altogether, the signs of increased concentration of glu-
cose at certain time-points or the elevated cumulative AUC
in the experimental animals during GTT compare to the
control group can pinpoint the impaired glucose tolerance.
Moreover, the initial spike response is generally referred to as
first-phase insulin release, and the subsequent decrease is
considered to represent the less-prominent but sustained
the second phase. Normally, partial or complete loss of the
first phase of glucose-induced insulin release is
a characteristic deterioration in the early stages of type 2
diabetes.46 Still, the researchers should be aware that glucose
tolerance and insulin action are not equivalent and try to
avoid the over-interpretation of results, additional more
detailed studies are certainly required (e.g. euglycemic
clamp).5,7
Nevertheless, ITT helps to determine the sensitivity of
insulin-responsive tissues. The degree to which glucose
falls following the insulin bolus is indicative of whole-
body insulin action. The data should be presented as
a time course of absolute blood glucose measurements
(Figure 3B), as reverse AUC, and additionally by percen-
tual changes in fasting glucose. The impaired IR becomes
apparent if insulin administration is less effective in
lowering blood glucose levels compared with the control
group.
Additionally, few more supplementary metabolic
tests to assess glucose metabolism have been developed.
Although they are of little value, they can be extraordi-
narily helpful to add substantive data and properly char-
acterize impaired glucose homeostasis and accurately
assess metabolic phenotypes in the mice (Table 2).
Conclusions
Metabolic tolerance tests are among the key methods in
experimental animal research. They are easy to per-
form, non-invasive and affordable. However, the
improper technical accuracies can dramatically alter
the reliability and reproducibility of the results. Here,
we provided an easy to follow very detail protocol that
allows the performance of GTT and ITT in mice. It is
simple to implement and can be quickly used by skilled
scientists. Furthermore, we specify some important fac-
tors that should be taken into account, including sex-,
age-, and strain-related differences and include some
practical considerations of the procedure design. We
hope that our review will help to successfully establish
these methods in other laboratories in order to obtain
reliable and reproducible results. We also think that
these protocols fully comply with the 3Rs principle of
animal experimentation and support the basis of new
European animal welfare rules.
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Figure 3 GTT (A) and ITT (B) in C57BL/6J, 20 weeks old female mice fed with chow diet. (A) After 12 hrs, fasting animals received i.p. injection of 1.5 g/kg glucose. The
blood glucose levels (mg/dl) were measured at different time points using hand-held glucometer. (B) Mice were fasted for 6 h and glucose response to i.p. insulin
administration (0.75 IU/kg) was measured at the indicated time (n=5).
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DM, Diabetes Mellitus; IR, Insulin Resistance; GTT,
Glucose Tolerance Test; HFD, High fat diet; i.p.,
Intraperitoneal Injection; ITT, Insulin tolerance test; MTT,
Metabolic tolerance test; OG, Oral gavage; SC, Stem cell;
TT, Tolerance test; T2DM, Type 2 diabetes mellitus.
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